A Phase 1 Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Activity of FP002 in Subjects With Advanced Malignancies
Latest Information Update: 17 Aug 2023
At a glance
- Drugs FP-002-Fapon-Biopharma (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Fapon Biopharma
Most Recent Events
- 09 Aug 2023 Status changed from not yet recruiting to recruiting.
- 30 Jul 2023 Status changed from planning to not yet recruiting.
- 24 Feb 2023 New trial record